

Dalton Transactions

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Influence of Self-assembly on Intercalative DNA Binding Interaction of**
2 **Double-chain Surfactant Co(III) Complexes Containing Imidazo[4,5-**
3 **f][1,10]phenanthroline and Dipyrido[3,2-d:2'-3'-f]quinoxaline ligands:**
4 **Experimental and Theoretical Study**

5

6 **Karuppiah Nagaraj^a, Gunasekaran Velmurugan^b, Subramanian Sakthinathan^a,**
7 **Ponnambalam Venuvanalingam^b and Sankaralingam Arunachalam^{a*}**

8 *^{a,b}School of Chemistry, Bharathidasan University, Tiruchirappalli-620 024, India.*

9

10 A new class of surfactant Co(III) complexes, cis-[Co(ip)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (**1**) and cis-
11 [Co(dpq)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (**2**) (ip = imidazo[4,5-f][1,10]phenanthroline, dpq =
12 dipyrido[3,2-d:2'-3'-f]quinoxaline), have been synthesized and characterized by various
13 spectroscopic and physico-chemical techniques. The critical micelle concentration (CMC) values
14 of these complexes in aqueous solution were obtained from conductance measurements. The
15 specific conductivity data (at 303, 308, 313, 318 and 323K) served for the evaluation of the
16 temperature-dependent CMC and the thermodynamics of micellization (ΔG_m^0 , ΔH_m^0 and ΔS_m^0).
17 The trend in DNA-binding affinities and the spectral properties of a series of complexes, cis-
18 [Co(ip)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (**1**) and cis-[Co(dpq)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (**2**), have been
19 experimentally and theoretically investigated. The experimental results indicate that the size and
20 shape of the intercalated ligand and hydrophobicity of the complexes have a marked effect on the
21 binding affinity of complexes to CT DNA in intercalation mode, and the order of their intrinsic
22 DNA-binding constants K_b is $K_b(\mathbf{1}) < K_b(\mathbf{2})$. In addition, the influence of the extended aromatic
23 ring and optical properties of the complexes can be reasonably explained by applying the DFT
24 calculations. The energy gap between HOMO and LUMO indicates that these complexes are
25 prone to interact with CT DNA. Further, molecular docking calculations have also been
26 performed to understand the nature of binding of the complexes and the result confirms that the
27 complexes interact with CT DNA through the alkyl chain. The cytotoxic activity of these
28 complexes on human liver carcinoma cancer cells were determined adopting MTT assay and
29 specific staining techniques, which revealed that the viability of the cells, thus treated was

30 significantly decreased and the cells succumbed to apoptosis as seen in the changes in the
31 nuclear morphology and cytoplasmic features.

32

33 *Corresponding author: S. Arunachalam; Phone: 91-431-2407053; Fax: 91 431 2407043/
34 2407045; E-mail: arunasurf@yahoo.com

35

36 **Introduction**

37 The understanding of the physical nature of DNA cationic surfactant interaction has primary
38 importance due to its significance in biomedical applications, particularly as efficient gene
39 delivery vectors [1]. In cationic detergents between DNA into discrete particles each consisting
40 of a single nucleic acid molecule [2,3], which is released fast into cells with accompanying
41 decondensation. This interesting feature of DNA-surfactant interaction has prompted biophysical
42 characterization of complexes of large DNA molecules with various surfactants [4,5]. Many
43 factors are reported to affect efficient gene transfection including the type of nanoscale structure
44 and the surface charge of DNA/surfactant complex. It is realized that strong DNA/cationic
45 surfactant interaction can help to compact DNA, yielding complexes of small size [6-9]. The
46 cooperative binding of cationic surfactants on DNA chains is primarily driven by both
47 electrostatic attraction and hydrophobic effect. The cationic surfactant can be varied by the
48 molecular structures including conventional single-tailed surfactants [10], Gemini surfactants
49 [11], double-tailed surfactants [12], etc.

50 The mode of action of many drugs in clinical use for the treatment of cancer, genetic
51 disorders, and viral diseases is believed to be based on their binding to nucleic acids and
52 subsequent modification of the genetic material [13]. Ribonucleic acid (RNA) also plays
53 essential role in normal biological process as well as in the progression of many diseases that led
54 to growing interests in exploiting in designing of a new class of therapeutics [14-16]. A number
55 of small organic molecules are endowed with cytotoxic properties that are exerted through highly
56 specific but non-covalent and reversible interactions with nucleic acid structures [17,18]. The
57 non-covalent interactions are further classified in terms of intercalation and groove binding.
58 Intercalation occurs when planar aromatic molecules are sandwiched between two adjacent base

59 pairs of nucleic acids. Non-intercalative binding occurs in the major or minor grooves of nucleic
60 acids without inserting any part of the binding molecule between base pairs. The physical and
61 molecular basis of binding of natural alkaloids to nucleic acids has been a subject of extensive
62 study in the recent past [19-21]. The intercalating ligands constitute one of the most widely
63 studied groups as they form important class of compounds for cancer therapy [22]. We have been
64 interested in the synthesis and micelle forming properties of Co(III)/Cu(II) complexes containing
65 lipophilic ligands [23-33]. As in biology, such compounds may exhibit novel physical and
66 chemical properties with interesting and useful associated applications. In metal-based drugs, the
67 metal can coordinate ligands in a precise three-dimensional configuration, thus allowing the
68 tailoring of the molecule to recognize and interact with a specific molecular target [34-36]. This
69 is further enhanced by different chemical modifications of ligands. Moreover, metal complexes
70 easily undergo redox reactions and ligand substitution which allow them to participate in
71 biological redox chemistry and interact with biological molecules. It is remarkable that
72 investigations in this area are focused on the use of biologically active complexes formed by
73 essential ions, such as Co (III). In spite of the great effort and success in the study of surfactant
74 Co(III) complexes, such complexes still attract much attention due to the relative simplicity of
75 their synthesis and their interesting properties. Co(III) complexes of bipyridine and
76 phenanthroline chelators are of great interest since they exhibit numerous biological properties
77 such as antitumor, anticandida and antibacterial activity [37-39]. In order to guide the design and
78 synthesis of new complexes with excellent bioactivity, some important factors affecting DNA
79 binding affinities of such a kind of polypyridyl complexes, e.g., the planarity and substituted
80 phenanthroline properties of the intercalative ligands, as well as ancillary ligand effects, have
81 been experimentally summarized in certain scale [40,41a]. In addition to the experimental
82 studies, the transition metal polypyridyl complexes have also attracted many theoretical
83 chemists. Various theoretical researchers have been trying to correlate some theoretical
84 predictions to the experimental findings [41b and 41c].

85 In this paper, we report two surfactant Co(III) complexes, cis-
86 $[\text{Co}(\text{ip})_2(\text{C}_{12}\text{H}_{25}\text{NH}_2)_2](\text{ClO}_4)_3$ (**1**) and cis- $[\text{Co}(\text{dpq})_2(\text{C}_{12}\text{H}_{25}\text{NH}_2)_2](\text{ClO}_4)_3$ (**2**) are synthesized
87 and characterized (Scheme 1 and 2). The trend in DNA-binding affinities and the spectral
88 properties of a series of surfactant Co(III) polypyridyl complexes were experimentally and
89 theoretically studied. The DNA binding constants K_b of the complexes were determined

90 systematically with spectrophotometric titration. DFT calculations were performed to rationally
91 explain the binding trend and the molecular docking studies carried out to obtain detailed binding
92 information of the complexes with CT DNA. This paper is mainly focused on experimentally
93 revealing the trend in DNA binding affinities of such a type of surfactant Co(III) polypyridyl
94 complexes and on theoretically attempting to understand them in order to effectively control the
95 DNA binding affinities of the complexes by selecting some suitable modified phenanthroline
96 ligands. This structural feature offers the chance for them to be a candidate for DNA-binding
97 reagents. The cytotoxicity of these surfactant Co(III) complexes against human liver carcinoma
98 cancer cells are also reported.

99

100 **Results and discussion**

101 **Critical micelle concentration (CMC) and thermodynamics of micellization**

102 The specific conductivity of the surfactant Co(III) complexes increases with the complex
103 concentration and temperature. When plots are made of [complex] versus specific conductivity,
104 the slope is reduced after a particular value of concentration. This particular value of
105 concentration at which slope of the plot changes shows micellization and this concentration is
106 chosen as CMC. Fig. 1 and SI (Supplementary Information) Fig. 1 illustrates that the plot for the
107 complexes **(1)** and **(2)**. It was observed that the CMC values increased with increase in the
108 temperature for a given system. This behavior may be related to two competitive effects. First, an
109 increase in temperature causes a decrease in hydration in the hydrophilic group, which favors
110 micellization. Second, an increase in temperature also disrupts the water surrounding the
111 hydrophobic group, and this retards micellization. The relative magnitude of these two opposing
112 effects will determine CMC behavior. The study of CMC versus temperature is often undertaken
113 to obtain information on hydrophobic and head group interactions. This involves deriving
114 various thermodynamic parameters of micelle formation [56-61]. The thermodynamic
115 parameters of micellization for the surfactant Co(III) complexes are presented in Tables 1 and SI
116 Table 1. The observed more negative Gibbs free energy of micellization indicates more favored
117 micellization for the system under study. Moreover, since the changes of CMC with temperature
118 are small, the value of ΔH_m^0 and ΔS_m^0 must be rather inaccurate and should be considered as

119 only approximate. As mentioned in our previous reports [23,25,28,29,31], the CMC values for
120 surfactant Co(III) complexes in the present study were also very low compared to those of the
121 simple organic surfactants. Thus it is suggested that our metal surfactant complexes have more
122 capacity to associate themselves forming aggregates than the ordinary synthetic organic
123 surfactants. Moreover, introduction of a metal complex to the hydrophilic part of the amphiphile
124 can remarkably enhance the ability of aggregation.

125

126 **DNA binding studies**

127 **Electronic absorption spectral studies**

128 Titration with UV spectroscopy is an effective method to examine the binding mode of nucleic
129 acid with metal complexes since the observed changes of the spectra may give evidence of the
130 existing interaction mode [62]. Thus, in order to provide evidence for the possibility of binding
131 of complexes to DNA, spectroscopic titration of the solutions of the surfactant Co(III) complex
132 with DNA has been performed. The UV spectra have been recorded for a constant DNA
133 concentration in different [compound/DNA] mixing ratios (r) and are shown in Fig. 2 and 3 and
134 SI Fig. 3 and 4. As seen from the Figures. 2,3 and SI Figures 3,4 with the increase of the
135 concentration of CT DNA, the absorption spectrum of surfactant Co(III) complex **(1)** shows
136 hypochromism 28% for below CMC and 31% for above CMC and complex **(2)** shows
137 hypochromism 34% for below CMC and 37% for above CMC with slight red shift on the
138 addition of increasing amounts of DNA. Hypochromism is suggested to arise due to an
139 intercalative mode of binding involving a strong stacking interaction between extending
140 aromaticity of ligand and the base pairs of DNA [63]. Also Co(III) complex containing long
141 aliphatic chain enhances hydrophobic interaction strongly with intercalating the base pairs of
142 DNA. The observed spectroscopic changes are thus, consistent with intercalation of complexes
143 into the DNA base stacks. In order to further elucidate quantitatively the affinity of the surfactant
144 Co(III) complex to CT-DNA, the intrinsic binding constant, K_b has been determined using the
145 equation [64],

146

$$[\text{DNA}] / (\varepsilon_a - \varepsilon_f) = [\text{DNA}] / (\varepsilon_0 - \varepsilon_f) + 1 / K_b (\varepsilon_0 - \varepsilon_f)$$

147 where, [DNA] is the concentration of DNA expressed in base pairs ; ϵ_a , ϵ_f and ϵ_0 are the
148 apparent, free and fully bound Co(III) complex extinction coefficients. A plot of [DNA]/ ($\epsilon_a - \epsilon_f$)
149 versus [DNA] gives K_b as the ratio of the slope to intercept.

150 The K_b values of the surfactant Co(III) complexes with CT DNA are given in Table 2. In
151 complex **(1)**, which contains ip ligand, that is expected to be planar and possesses a smaller π
152 system than dpq, intercalation is lower [65-68]. Since the complex **(2)**, contains dpq ligand ($2.4 \times$
153 10^6 M^{-1} for below CMC and $3.1 \times 10^6 \text{ M}^{-1}$ for above CMC), it would provide an aromatic moiety
154 extending from the metal center through which overlapping would occur with the base pairs of
155 DNA by intercalation. Besides the binding constant at below CMC values are lower than that at
156 above the CMC values. Above cmc value the surfactant complex presents as both monomers as
157 well as micelles. Aggregation of complex molecules into micelles would reduce their ability to
158 bind to DNA. So there is a difference in K_b values at above cmc and below cmc values. Also the
159 K_b of surfactant Co(III) complexes is very much higher than that for the ordinary metal
160 complexes, like $[\text{Co}(\text{bpy})_3]^{3+}$ ($K_b, 9.3 \times 10^3 \text{ M}^{-1}$) [69], $[\text{Co}(\text{bpy})_2(\text{imp})]^{3+}$ ($K_b, 1.1 \times 10^4 \text{ M}^{-1}$) [70],
161 $[\text{Co}(\text{bpy})_3(\text{BHBMe})]^{2+}$ ($K_b, 1.23 \times 10^4 \text{ M}^{-1}$), $[\text{Co}(\text{bpy})_2(\text{BHBNO}_2)]^{2+}$ ($K_b, 2.06 \times 10^4 \text{ M}^{-1}$) [71],
162 $[\text{Co}(\text{ip})_2\text{Cl}_2]\text{Cl}$ ($K_b, 2.9 \times 10^3 \text{ M}^{-1}$), $[\text{Co}(\text{dpq})_2\text{Cl}_2]\text{Cl}$ ($K_b, 6.4 \times 10^3 \text{ M}^{-1}$) [72]. This implies that this
163 series of the complexes can intercalate between the base pairs of DNA and thus be protected by
164 DNA efficiently, since the hydrophobic environment inside the DNA helix reduces the
165 accessibility of solvent water molecules to the complex and the complex mobility is restricted at
166 the binding site. Such a trend is also in agreement with that in the binding constants (K_b).

167

168 **Trend in DNA-binding affinities of the complexes and theoretical explanations**

169 As reported in the literature DNA molecule is generally an electron-donor and the intercalated
170 complex is an electron-acceptor and there are π - π stacking interactions in the DNA-binding of
171 these complexes in intercalation mode. Higher HOMO energy of DNA molecule and lower
172 LUMO energy of the complex result in a stronger interaction between DNA and the complex.
173 Kurita and Kobayashi [73-75] have reported a simple calculation model and reported DFT
174 computed results for stacked DNA base-pairs with backbones. It should be a rather reasonable
175 approximation model for DNA, and thus should be useful for such a discussion. The optimized
176 geometries of the complexes **(1)** and **(2)** are given in SI Fig. 4 (SI-Supporting Information). To

177 gain further insight into the influence of the extended aromatic ring and trend in DNA-binding
178 activities of the complexes the combined molecular orbital energy level graph for complexes **(1)**
179 and **(2)** is given (SI Fig 5). The HOMOs and LUMOs are often used to relate the spectral
180 properties of complexes and provide decisive clues in designing new complexes. Therefore it is
181 essential to identify and understand the nature of various segments of the complex and their
182 individual contributions towards HOMOs and LUMOs. Hence, the contribution of various
183 fragments of the complexes has been analyzed using QMForge Program [76]. The complexes
184 have been segmented into three fragments, namely Co (Cobalt), L1 (equatorial ligand), L2 (alkyl
185 chain) and their corresponding percentage contributions to frontier molecular orbitals are
186 summarized in Table 3.

187 The complex **(2)** has the lowest band gap (3.07eV) due to the extension of aromatic ring
188 of the L1 destabilizing the HOMO levels. The frontier molecular orbital shows that the HOMO
189 of complex **(1)** and **(2)** is mainly localized on the L2 (93% and 99% respectively). The LUMO of
190 complex **(1)**, there is mainly centered on the L1 (85%) whereas in complex **(2)** it is mainly
191 localized on Co (d_{yz} 54%) and L1 (43%). On the other hand, the HOMO-1 to HOMO-3 of
192 complex **(2)** is localized on L2 of the complex. LUMO+1 of the complex **(1)** is mainly
193 composed of 53% Co (d_{yz}) and 45% of L1. However, extension of aromatic ring in the axial
194 position have a direct effect on the orbital energy of HOMO and as the result HOMO of complex
195 **(2)** is more stabilized than that of complex **(1)**. The LUMOs are not influenced by this ligand.

196 The calculated results indicate that the extension of aromatic ring in the axial position can
197 destabilize the energy of HOMO more significantly than those of the LUMO resulting in
198 narrower HOMO-LUMO energy gap. The LUMO of the complexes of **(1)** and **(2)** lie at -6.92eV
199 and -6.86eV respectively, which distribute predominantly on the intercalative ligands. The
200 predominant LUMO population on the intercalative ligands of the complexes should be
201 advantageous to accept the electron from base-pairs of DNA and the trend in the K_b is well
202 correlated with the LUMO energy values of the complexes.

203

204 **Molecular docking details**

205 The above experimental results show that these surfactant Co(III) complexes bind to DNA in the
206 intercalation mode and the DNA-binding affinities of these complexes increase in the order: **(1)**
207 < **(2)**. Obviously, there are subtle but detectable differences occurred in the DNA-binding
208 properties. Such differences may be resulted from the changes of geometric and electronic
209 structures of these complexes (especially the intercalative ligand) due to the different modified
210 phenanthroline on the intercalative ligand. Although the single crystal structures of these
211 surfactant Co(III) complexes have not been obtained as far, the DFT calculations can give us
212 some important parameters of the geometric structures of these complexes, as well as some
213 useful information on the electronic structures.

214 To understand the efficiency of a biologically active drug molecule, the knowledge of its
215 binding location in the CT DNA is very essential and significant. Moreover, the docking study
216 further corroborated the existence of interactions between the Co(III) complexes and DNA. Thus
217 the molecular docking calculations were performed and the most probable docked poses are
218 given in Fig. 4. As seen from the Fig. 4 clearly shows that both the complexes could fit well into
219 the CT DNA with a binding site of three base pairs, preferentially involving the G-C residues as
220 revealed by the docked structure. The availability of the extended alkyl chain makes the complex
221 could bind well to the hydrophobic interior of CT DNA. The complex **(2)** interacts with CT
222 DNA through intercalation and gains additional stabilization due to aromatic moiety extending
223 from the metal center. Thus, the complex **(2)** is found to have higher binding affinity than
224 complex **(1)**. In both the cases, the surfactant Co(III) complexes holding three base pairs is like
225 A-T, G-C, G-C to the outer surface, i.e., the groove of the CT DNA. Thus, the G-C regions seem
226 to facilitate a better fit of the complexes into the CT DNA. It is interesting to note that the
227 binding energy of complex **(1)** was 12.0 kcal mol⁻¹ less than that of complex **(2)** due to the π - π
228 stacking interaction of extending of aromatic moiety. The aromatic ring structure of surfactant
229 Co(III) complex having a long alkyl chain allows for torsional rotation in order to fit into the
230 narrower helical curvature of the CT DNA. This excellently agrees with the outcome of other
231 experiments (binding constant and spectroscopic studies). Thus, our molecular modeling studies
232 throw light on the binding modes by which these complexes interact with CT DNA and
233 complement the experimental observations.

234

235 Thermal denaturation studies

236 The dissociation of a duplex nucleic acid into two single strands results in significant
 237 hyperchromism around 260 nm. The binding of a metal complex to a nucleic acid induces a
 238 conformational change of the latter to alter so-called denaturation temperatures depending on the
 239 strength and mode of interactions between complex and nucleic acid. In the present work the
 240 melting curves of CT-DNA in the absence and presence of complex (1) and (2) are presented in
 241 SI Fig. 6. A T_m of CT-DNA in buffer was determined as for surfactant complexes under our
 242 experimental conditions ($74.0 \pm 0.2^{\circ}\text{C}$). The DNA intrinsic binding constant of the surfactant
 243 Co(III) complexes at T_m were calculated by using McGhee's equation (Eq. (4))[77], where T_m^0 is
 244 the melting temperature of CT-DNA alone, T_m is the melting temperature in the presence of the
 245 Co(III) complexes, ΔH_m is the enthalpy of DNA (per base pair), R is the gas constant, K is the
 246 DNA-binding constant at T_m , L is the free complex concentration (approximate by the total
 247 complex concentration) at T_m , and n is the size of the binding site.

$$248 \quad 1/T_m^0 - 1/T_m = (R/\Delta H_m) [\ln(1+KL)]^{1/n} \quad (4)$$

249 By substitution of the required parameters into Eq. (1), K was determined to be $6.68 \times$
 250 10^5 M^{-1} for the title complex at 85°C . Only few thermodynamic parameters such as free energy,
 251 enthalpy and entropy changes upon binding of metal complexes to DNA have been measured,
 252 although there have been many reports on the interaction of metal complexes with DNA. In fact,
 253 the thermodynamic parameter of DNA-complex formation is essential for a thorough
 254 understanding of driving forces of the binding of metal complexes to DNA [78]. The change of
 255 standard enthalpy was determined according to the van't Hoff's equation (Eq. (5)). The changes
 256 of standard free energy and standard entropy of the binding of the title complex to DNA were
 257 determined according to Eqs. (6) and (7), where K_1 and K_2 are the DNA-binding constants of the
 258 complex at the temperatures T_1 and T_2 , respectively. ΔG_T^0 , ΔH^0 , and ΔS^0 are the changes of
 259 standard free energy, standard enthalpy, and standard entropy of the binding of the titled
 260 complexes to CT-DNA, respectively.

$$261 \quad \ln(K_1/K_2) = \Delta H^0/R (T_1 - T_2/T_1 T_2) \quad (5)$$

$$262 \quad \Delta G_T^0 = -RT \ln K \quad (6)$$

$$\Delta G_T^0 = \Delta H^0 - T\Delta S^0 \quad (7)$$

The value of ΔH^0 is derived to be $-82.8 \text{ k J mol}^{-1}$ by substituting $K_1 = 1.17 \times 10^6 \text{ M}^{-1}$ ($T_1 = 298\text{K}$) and $K_2 = 6.68 \times 10^5 \text{ M}^{-1}$ ($T_2 = 358\text{K}$) into Eq. (4). By substituting $K_1 = 1.17 \times 10^6 \text{ M}^{-1}$ ($T_1 = 298\text{K}$) and $\Delta H^0 = -82.8 \text{ k J mol}^{-1}$ into Eqs. (5) and (6), $\Delta G_{298 \text{ K}}^0 = -34.6 \text{ k J mol}^{-1}$ and $\Delta S^0 = -16.2 \text{ J mol}^{-1} \text{ K}^{-1}$ at 25° C were derived. It is clearly observed from the experimental results that the complex formation for all the cases was spontaneous with similar negative ΔG^0 values. The negative binding free energy suggests that the energy of the complex-DNA adduct is lower than the sum of the energies of the free complex and DNA, and the binding of the titled complexes to CT DNA is favorable at room temperature. The possible explanation of the entropically driven DNA binding of these types of metal complexes has been discussed in details from the viewpoint of molecular interaction by Haq *et al.* [79] and by us earlier. The negative entropy implies that the degree of freedom of the titled complexes and DNA conformation is reduced upon complex-DNA binding. According to the thermodynamic data, interpreted as follows, the model of interaction between a drug and biomolecule can be concluded as [80]: (1) $\Delta H < 0$ and $\Delta S < 0$, hydrophobic forces; (2) $\Delta H > 0$ and $\Delta S > 0$, van der Waals interactions and hydrogen bonds; (3) $\Delta H > 0$ and $\Delta S < 0$, electrostatic interactions [81]. In order to elucidate the interaction of our complex with DNA, the thermodynamic parameters were calculated. When we apply this analysis to the binding of the complex with CT DNA, we find that $\Delta H < 0$ and $\Delta S < 0$. Therefore, intercalations via hydrophobic interactions are probably the main forces in the binding of the investigated complexes to CT DNA. These results provide that these surfactant Co(III) complexes may interact with CT DNA in an intercalation mode.

284

285 **Competitive binding between ethidium bromide (EB) and surfactant Co(III) complexes**

286 In order to investigate the mode of binding of the surfactant Co(III) complexes to DNA, the
287 competitive binding experiment using ethidium bromide ($2 \times 10^{-5} \text{ M}$) was carried out. Ethidium
288 bromide (EB) is one of the most sensitive fluorescent probes that can bind to DNA [82-83]. The
289 emission spectra of EB bound to DNA in the absence and the presence of the surfactant Co(III)
290 complexes (**1**) and (**2**) are given in Fig. 5 and SI Fig. 8. The addition of these complexes to DNA
291 pretreated with EB caused an appreciable reduction in the emission intensity, indicating that the

292 replacement of the EB fluorophore by the complex results in a decrease of the binding constant
293 of ethidium bromide to DNA. According to the classical Stern-Volmer equation [84]:

$$294 \quad I_0/I = 1 + K_{sv} [Q]$$

295 where I_0 and I are the fluorescence intensities in the absence and the presence of the complex,
296 respectively. K_{sv} is a linear Stern–Volmer constant and r is the ratio of the total concentration of
297 the complex to that of DNA. The fluorescence quenching of EB bound to DNA by the surfactant
298 Co(III) complexes **(1)** and **(2)** are shown in SI Fig. 8. The quenching plots illustrate that the
299 quenching of EB bound to DNA by the surfactant Co(III) complexes are in good agreement with
300 the linear Stern-Volmer equation, which also indicates that the complexes bind to DNA. In the
301 plot of I_0/I versus $[\text{complex}]/[\text{DNA}]$, K_{sv} is given by the ratio of the slope to intercept. The K_{sv}
302 values for our surfactant Co(III) complexes **(1)** and **(2)** are 0.157 and 0.183, respectively. These
303 data suggest that the interaction of surfactant Co(III) complex **(2)** with DNA is stronger than
304 complex **(1)**, which is consistent with the spectral results described above.

305

306 **Electrochemical studies**

307 The electrochemical investigations of metal-DNA interactions can provide a useful complement
308 to spectroscopic methods, e.g., for non-absorbing species, and yield information about
309 interactions with both the reduced and oxidized form of the metal [85]. In general, the
310 electrochemical potential of a small molecule will shift positively when it intercalates into DNA
311 double helix, and it will shift in a negative direction in the case of electrostatic interaction with
312 DNA [86]. The complete scan in the range +1.0 V to -1.5 V of surfactant Co(III) complexes in
313 the absence of DNA shows a cathodic wave at -0.72 V and an anodic wave at 0.01 V for
314 complex **(1)** and a cathodic wave at -0.24 V and an anodic wave at 0.06 V for complex **(2)** (SI
315 Figures 9 and 10). This quasi-reversible wave can be assigned to the couple Co(III)/Co(II).
316 Complexes **(1)** and **(2)** have similar behavior and the corresponding potentials are given in Table
317 5. The quasi-reversible redox couple Co(II)/Co(III) for each complex in buffer solution has been
318 studied upon addition of CT DNA and the corresponding potentials as well as their positive
319 shifts are given in Table 4. No new redox peaks appeared after the addition of CT DNA to each
320 complex, but the current intensity of all the peaks decreased significantly, suggesting the

321 existence of an interaction between each complex and CT DNA. The decrease of current
322 intensity can be attributed to an equilibrium mixture of free and DNA bound complex to the
323 electrode surface [86]. For increasing amounts of CT DNA, the cathodic potential E_{pc} for all
324 complexes shows a positive shift. Hence the positive shifts in the CV peak potential of surfactant
325 Co(III) complexes are indicative of intercalation of these complexes into the DNA [86].

326

327 **Circular Dichroism Studies**

328 CD spectra is a useful technique in diagnosing changes in DNA morphology during drug–DNA
329 interactions as the CD signals are quite sensitive to the mode of DNA interactions with small
330 molecules [87]. The characteristic CD spectra of right-handed B form DNA consist of two
331 bands: a positive band (275 nm) due to the base stacking and a negative band (245 nm) due to
332 the right-handed helicity. The observed changes of CD signals of DNA are usually assigned to
333 the corresponding changes in DNA structure [87]. It is generally accepted that the classical
334 intercalation enhances the base stacking and stabilizes helicity, and thus increases intensities of
335 the both bands, whereas simple groove binding and electrostatic interaction of small molecules
336 show less or no perturbation on the base stacking and helicity bands [88]. In SI Fig. 11, the CD
337 spectrum of CT DNA was monitored in the presence of increasing amounts of complexes **(1)** and
338 **(2)**. The positive band showed an increase in molar ellipticity with a red shift of the band
339 maxima when the complex concentration was progressively increased. This increase in intensity
340 with a red shift in positive bands suggests that surfactant Co(III) complexes binds to CT DNA
341 via intercalation.

342

343 **Viscosity measurements**

344 The binding modes of the surfactant Co(III) complexes were further investigated by viscosity
345 measurements. In the absence of crystallographic structure data, hydrodynamic methods, which
346 are sensitive to increase in DNA length, are regarded as the least ambiguous and the most critical
347 tests of binding in solution [88a]. Optical or photophysical probes generally provide necessary,
348 but not sufficient clues to support an intercalative binding model. Under appropriate conditions

349 intercalation causes a significant increase in the viscosity of DNA solutions due to the separation
350 of base pairs at intercalation sites and, hence, increase the overall DNA contour length whereas
351 ligands that bind exclusively in the DNA grooves, groove-face or electrostatic interactions
352 typically cause a bend (or kink) in DNA helix reducing its effective length and thereby its
353 viscosity. The effects of the surfactant Co(III) complexes **(1)** and **(2)** on the viscosity of DNA
354 are shown in SI Fig. 12. Upon addition of increasing the amounts of the titled complexes, the
355 relative viscosity of DNA increase steadily. These results suggest that the titled surfactant Co(III)
356 complexes intercalates between the base pairs of DNA, in agreement with the above
357 experimental results.

358

359 **Cytotoxicity Studies**

360 **MTT assay**

361 We examined the cytotoxicity of the effects of these surfactant Co(III) complexes on
362 cultured HepG2 liver cancer cells by exposing cells for 24 and 48 h to the medium containing the
363 complex1 at 8.3-74.7 μ m (10-90 μ g/mL) and complex 2 at 8.0-72.0 μ m (10-90 μ g/mL)
364 concentration. *In vitro* antitumor activity of these compounds was determined according to the
365 percentage of nonviable cells (%NVC) which was calculated by the following equation:

$$366 \text{NVC}\% = [\text{number of NVC}/\text{total number of cells}] \times 100$$

367 The results of these experiments are summarized in Table 5. As shown in table increasing the
368 concentration of surfactant Co(III) complexes was accompanied by progressive increase in the
369 NVC %. This is due to the fact that by increasing the concentration of cationic surfactant
370 complexes the adsorption of ions on cell membranes increases, leading to increase in penetration
371 and antitumor activity.

372 The results of the cytotoxic activity on human tumor cell lines was determined according
373 to the dose values of drug exposure required to reduce survival in the cell lines to 50% (IC_{50}). It
374 should be noted that the action of the complex as antitumor agents is found to be dependent on
375 the type of tumor cell line (HepG2) tested but, as shown from the results, surfactant Co(III)
376 complexes show excellent cytotoxic activity against tumor cell lines (HepG2) and, at very low
377 concentrations, reduces the survival to 50%. This is due to the fact that cobalt complexes have a

378 capacity to reduce the energy status in tumors as well as to enhance tumor hypoxia [88b and
379 88c], which also influences their antitumor activities. It may be also concluded that the level of
380 cellular damage inflicted by these complex depends on the nature of their axial ligands. It is
381 known that phenanthroline-containing metal complexes have a wide range of biological activities
382 such as antitumor, antifungal, apoptosis [89,90] and interaction with DNA inhibiting replication,
383 transcription and other nuclear functions and arresting cancer cell proliferation so as to arrest
384 tumor growth. In general, the high selectivity of action by redox-active cobalt complexes upon
385 tumors is due to their specific reactivity [91]. From these results, surfactant Co(III) complexes
386 seems to offer promise due to the high electron affinity of the metal (which increases its ability
387 to bind DNA) and the ready reducibility of the compounds [92].

388

389 **Fluorescence Microscopic Analysis of apoptotic cell death (AO and EB staining)**

390 AO/EB staining adopting fluorescence microscopy also revealed apoptosis from the perspective
391 of fluorescence. After HepG2 liver cancer cells were exposed to the concentrations of surfactant
392 Co(III) complexes for 24 h. In this study, we used acridine orange/ethidium bromide (AO/EB)
393 double staining assay [93]. Acridine orange is taken up by both viable and nonviable cells and
394 emits green fluorescence if interrelated into double stranded nucleic acid (DNA). Ethidium
395 bromide is taken up only by nonviable cells and emits red fluorescence by intercalation into
396 DNA. We distinguished four types of cells according to the fluorescence emission and the
397 morphological aspect of chromatin condensation in the stained nuclei: (1) viable cells showing
398 light green fluorescing nuclei with highly organized structure; (2) early apoptotic cells having
399 bright green fluorescing nuclei with chromatin condensation and nuclear fragments; (3) late
400 apoptotic cells having orange to red fluorescing nuclei with condensed or fragmented chromatin;
401 and (4) necrotic cells having red fluorescing without chromatin fragmentation. Viable cells have
402 uniform bright green nuclei with organized structure. Apoptotic cells have orange to red nuclei
403 with condensed or fragmented chromatin. Necrotic cells have a uniformly orange to red nuclei
404 with condensed structure (Fig. 6). Our results indicate that surfactant Co(III) complexes induced
405 apoptosis at the concentrations evaluated, in agreement with the cytotoxic results. The results
406 suggest that the complex treatment caused more cells to take to death in HepG2 liver cancer
407 cells.

408

409 Apoptosis Detection Hoechst 33342 DNA Staining

410 It is possible to perform apoptosis detection assay with Hoechst 33342 (Sigma B-2262), but the
411 increase in fluorescence seen in the apoptotic cells may be less dramatic. Hoechst dyes can also
412 be obtained from Molecular Probes. H33342 is a "vital" DNA stain that binds preferentially to
413 A-T base-pairs. The cells require no permeabilization for labeling, but do require physiologic
414 conditions since the dye internalization is an active transport process. This condition typically
415 varies among cell types (Stander *et al.*, 2009). To investigate if HepG2 liver cancer cells were
416 triggered to undergo apoptosis due to the exposure of surfactant Co(III) complexes,
417 morphological changes of apoptosis were performed in the treated cells by Hoechst 33342
418 staining. Apoptosis is one of the major pathways that lead to the process of cell death. After the
419 cells were treated with IC_{50} concentrations of surfactant Co(III) complexes for 24 and 48 h the
420 cells were observed for cytological changes adopting Hoechst 33342 staining. The observations
421 revealed that the complexes brought about cytological changes such as chromatin fragmentation,
422 binucleation, cytoplasmic vacuolation, nuclear swelling, cytoplasmic blabbing and late apoptosis
423 indication of dot-like chromatin and condensation (Fig. 7) whereas untreated cells did not show
424 such changes. Data collected from the manual counting of cells with normal and abnormal
425 nuclear features. Both apoptotic and necrotic cells increased in dose-dependent manner. These
426 data clearly indicated that higher doses of surfactant Co(III) complexes resulted in remarkable
427 chromatin condensation and nuclear fragmentation in HepG2 liver cancer cells.

428

429 Conclusions

430 In this work the surfactant Co(III) complexes containing polypyridyl ligand has been
431 synthesized and successfully characterized. The cmc values of these surfactant Co(III)
432 complexes are very low showing more capacity to associate themselves, forming aggregates,
433 compared to those of ordinary synthetic organic surfactants. The experimental results indicate
434 that these surfactant Co(III) complexes could binds to CT DNA by intercalative mode and the
435 binding constant of complex **(1)** is smaller than that of complex **(2)**. Computations support this
436 and further it reveals that the intercalative binding between surfactant Co(III) complexes and CT

437 DNA is due to the presence of extending aromaticity of ligand and a long aliphatic chain of the
438 complexes. Furthermore, it was observed that surfactant Co(III) complex exhibits considerable
439 ability to bind with the G-C-rich sequence of DNA. As the aromatic moiety extending from the
440 metal centre, the binding ability increases. Both the surfactant Co(III) complexes are cytotoxic to
441 human liver carcinoma cancer cells. Therefore, these complexes might prove to be of application
442 in target-based cancer therapy since the mechanism of cell death appears to be essentially
443 apoptosis, but necrosis also is one of the desired endpoints in cancer therapy.

444 **Experimental Section**

445 **Materials and methods**

446 All the reagents were of analytical grade (Sigma-Aldrich and Merck). Calf thymus DNA
447 obtained from Sigma-Aldrich, Germany, was used as such. The spectroscopic titration was
448 carried out in the buffer (50 mM NaCl–5 mM Tris–HCl, pH 7.1) at room temperature. A solution
449 of calf thymus DNA in the buffer gave a ratio of UV absorbance ~1.8–1.9:1 at 260 and 280 nm,
450 indicating that the DNA was sufficiently free of protein [38]. Milli-Q water was used to prepare
451 the solutions. The ligands, ip and dpq were synthesized by using previously published
452 procedures [39,40]. The precursor Co(III) complexes, cis-[Co(LL)₂Cl₂]Cl (where LL₂ = ip and
453 dpq) were prepared by a similar method to the previously published reports [41,42]. Absorption
454 spectra were recorded on a UV–Vis Spectrophotometer using cuvettes of 1 cm path length, and
455 emission spectra were recorded on a JASCO FP 770 spectrofluorimeter. FT-IR spectra were
456 recorded on a FT-IR Perkin Elmer spectrophotometer with samples prepared as KBr pellets. ¹H
457 NMR spectra were recorded on a BRUKER 500 MHz Spectrometer using DMSO as solvent.
458 Conductivity studies were carried out on aqueous solutions of the complexes with an Elico
459 conductivity bridge type CM 82 and a dip-type cell with a cell constant of 1.0. The carbon,
460 hydrogen and nitrogen content of the complexes were determined on a CHNS Elemental
461 Analyzer-elementar (Model: Vario EL III) available at Sophisticated Analytical Instrument
462 Facilities (SAIF), Central Electrochemical Research Institute (CECRI) Karaikudi, India. The
463 anticancer studies were carried out at PCBS Research Centre, Pondicherry University.

464 **Synthesis of double chain surfactant Co(III) complexes**

465 **Preparation of cis-[Co(ip)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (1)**

466 To a solution of cis-[Co(ip)₂Cl₂]Cl (0.53 g) dissolved in water (10 mL), dodecylamine
467 (0.26 mL) in ethanol (2 mL) was added dropwise over a period of 30 min. The mixture was set
468 aside at room temperature for 4 days until no further change was observed. Afterwards, a
469 saturated solution of sodium perchlorate in perchloric acid was added. A pasty solid mass
470 separated out slowly and it was filtered off, washed with small amounts of alcohol followed by
471 acetone, and then dried in air. The semi-dried material was further dried over fused calcium
472 chloride in a drying pistol and stored in a vacuum desiccator. UV λ_{\max} (CH₂Cl₂)/nm 248 (π - π^*),
473 290 (n- π^*), 370 (MLCT). FT-IR (KBr)/ cm⁻¹ 786, 725, 1384 (C=N), 2914, 2852, 1104 and 621.
474 ¹H NMR (400 MHz; CDCl₃): δ 0.96 (m, 6H, CH₃), 1.29-4.02 (44H, Aliphatic-H), 4.21 (m, 2H,
475 NH₂), 4.41(m, 2H, NH₂), 5.43 (m, 2H, NH), 7.34 (m, 12H, Ar-H), 7.67 (s, 2H, Ar-H). ¹³C NMR
476 (400 MHz; CDCl₃): δ 24.27, 24.30, 29.32, 32.92, 33.12, 34.77, 35.01 (Aliph-C's), 117.83,
477 118.58, 118.81, 120.92, 127.37, 127.86, 128.35, 129.35, 129.79, 137.17, 138.27, 148.08, 150.08,
478 160.30, 161.60, 165.37, 165.67 (Ar-C's). Calcd. for C₅₃H₇₈CoN₁₀: C, 52.60, H, 6.07, N 11.75.
479 Found: C 51.60, H, 6.30, N, 11.83.

480 **Preparation of cis-[Co(dpq)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ (2)**

481 The cis-[Co(dpq)₂(C₁₂H₂₅NH₂)₂](ClO₄)₃ complex was synthesized similar to the
482 procedure described above, except that we have added dpq ligand in the reaction mixture instead
483 of ip ligand. [Caution: Perchlorate salts of metal complexes with organic ligands are potentially
484 explosive. Only small amounts of the material should be prepared and handled with great care].
485 UV λ_{\max} (CH₂Cl₂)/nm 250 (π - π^*), 293 (n- π^*), 374 (MLCT). FT-IR (KBr)/ cm⁻¹ 791, 728, 1386
486 (C=N), 2912, 2850, 1100 and 620. ¹H NMR (400 MHz; CDCl₃): δ 0.98 (m, 6H, CH₃), 1.18-4.31
487 (44H, Aliphatic-H), 3.72-3.82 (m, 4H, NH₂), 5.43 (m, 2H, NH), 6.5-7.8 (16H, Ar-H). ¹³C NMR
488 (400 MHz; CDCl₃): δ 24.27, 24.30, 29.32, 32.92, 33.12, 34.77, 35.01 (Aliph-C's), 117.83,
489 118.58, 118.81, 120.92, 127.37, 127.86, 128.35, 129.35, 129.79, 137.17, 138.27, 148.08, 150.08,
490 160.30, 161.60, 165.37, 165.67 (Ar-C's). Calcd. for C₅₅H₇₈CoN₁₀: C, 52.62, H, 6.11, N 11.38.
491 Found: C 52.67, H, 6.17, N, 11.59.

492 **Estimation of amount of Cobalt in Complexes 1 and 2**

493 Cobalt content in the surfactant Co(III) complexes was estimated according to Kitson
494 [47]. Briefly, a known weight of the complex was reduced with tin and concentrated
495 hydrochloric acid. The reduced aqueous cobalt(II) ion was made up to 10 mL in volumetric flask

496 using 0.1 M perchloric acid. 2 mL of this solution and 1 mL of 50% ammonium thiocyanate
497 solution were pipetted out into a 10 mL volumetric flask and made up to the mark with acetone.
498 The absorbance of this solution was measured at 625 nm against a reagent blank. From the
499 absorbance, the concentration of cobalt was calculated. The percentage of cobalt thus obtained
500 for our surfactant Co(III) complexes is Co 4.98 (4.89) for complex (1) and Co 4.88 (4.71) for
501 complex (2).

502 **Estimation of critical micelle concentration (CMC) values**

503 The CMC values of the complexes were determined conductometrically using a specific
504 conductivity meter. The conductivity cell was calibrated with KCl solution in the appropriate
505 concentration range. Various concentrations of surfactant Co(III) complexes were prepared in the
506 appropriate range in aqueous solution. The conductivity of these solutions was measured at 303,
507 308, 313, 318 and 323K. The temperature of the thermostat was maintained constant, to be
508 within ± 0.01 . The conductance was measured after thorough mixing and temperature
509 equilibration at each dilution. The establishment of equilibrium was checked by taking a series of
510 readings at 15 min intervals until no significant change occurred. At all temperatures a break in
511 the conductance versus concentration in the plots, characteristic of micelle formation, was
512 observed. The CMC values were determined by fitting the data points above and below the break
513 to two equations of the form $y = mx + c$ and solving the two equations simultaneously to obtain
514 the point of intersection. Least-squares analysis was employed, and the correlation coefficients
515 were greater than 0.98 in all the cases.

516 **DNA binding experiments**

517 The DNA concentration per nucleotide was determined adopting absorption spectroscopy
518 using the known molar extinction coefficient value of $6600 \text{ M}^{-1} \text{ cm}^{-1}$ at 260 nm [48]. Absorption
519 titrations were performed by using a fixed surfactant Co(III) complex concentration to which
520 increments of the DNA stock solution were added. Surfactant Co(III) complex–DNA solutions
521 were incubated for 10 min before the absorption spectra were recorded. For fluorescence
522 experiments, DNA was pretreated with ethidium bromide (EB) for 30 min. The surfactant
523 Co(III) complexes were then added to this mixture and the effect on the emission intensity was
524 measured. The samples were excited at 515 nm and emission was observed between 500 and 700
525 nm. These experiments were carried out in 50 mM NaCl–5 mM Tris–HCl at pH 7.1 in aqueous
526 media. All voltammetric experiments were performed in a single compartment cell with a three-

527 electrode configuration on a EG&G PAR 273 potentiostat equipped with a personal computer.
528 The working electrode was a glassy carbon and the reference electrode was standard calomel
529 electrode. A platinum wire was used as the counter electrode. The supporting electrolyte was
530 phosphate buffer at pH 7.1. Solutions were deoxygenated by purging with nitrogen gas for 15
531 min prior to measurements; during measurements a stream of nitrogen gas was passed over the
532 solution. Circular dichroic experiments were recorded on a JASCO J-716 spectropolarimeter
533 (220-320 nm) were obtained at 25°C using a quartz cell of 1cm path length. Each CD spectrum
534 was collected after averaging over at least 4 accumulations using a scan speed of 100 nm min⁻¹
535 and 1s response time. The region between 220nm and 320 nm was scanned for each sample. The
536 spectra was recorded in the absence and in the presence of surfactant Co(III) complexes.
537 Viscosity experiments were carried out using an Ubbelodhe viscometer maintained at a constant
538 temperature of 29.0 ± 0.1°C. Calf thymus DNA (1×10⁻⁵M) sample solutions were prepared by
539 sonication in order to minimize complexities arising from DNA flexibility. Data were presented
540 as $(\eta / \eta^0)^{1/3}$ versus binding ratio, where η is the viscosity of DNA in the presence of the
541 complex, and η^0 is the viscosity of DNA alone. The relative viscosity was calculated according
542 to the relation $\eta = (t - t_0)/t_0$, where t_0 is the flow time for the buffer and t is the observed flow
543 time for DNA in the presence and absence of the complex [49].

544

545 **Cytotoxicity assay**

546 The cytotoxicity of the surfactant Co(III) complexes were measured in the MTT (3-(4,5-
547 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay as described by us earlier [50].
548 The complexes were first dissolved quantitatively in dimethyl sulfoxide (DMSO, Sigma, USA)
549 to make the stock solution. Briefly, cells were seeded at a density of 5 × 10⁴ HepG-2 liver cancer
550 cells/well into 96-well plates. After 24 h, the cells were treated with surfactant cobalt (III)
551 complexes at various concentration (10, 30, 60, 90 µg/ml) and incubated for 24 and 48 hours as
552 indicated. At the end of the incubations, 10µl of 3-(4-5 dimethylthiozol-2-yl) 2-5 diphenyl-
553 tetrazolium bromide (MTT) (5 mg/ml) per well was added and incubated in dark at 37°C for 4
554 hours. The formazan crystals formed after 4 hours were solubilized in 100µl of DMSO after
555 aspirating the medium. The absorbance was monitored at 570 nm (measurement) and 630 nm
556 using a 96 well plate reader (Bio-Rad, Hercules, CA, USA). The IC₅₀ value was defined as the
557 concentration of compound that produced a 50% reduction of cell viability.

558

559 Evaluation of apoptosis (Acridine orange and ethidium bromide staining)

560 Acridine orange and ethidium bromide staining was performed as described by Spector *et*
561 *al.* [50]. Twenty-five microliters of cell suspension of each sample (both attached, released by
562 trypsinization, and floating), containing 5×10^5 cells, was treated with AO and EB solution (one
563 part of 100 mg/mL AO and one part of 100 mg/mL EO in PBS) and examined under a
564 fluorescent microscope (Carl Zeiss, Germany) using an UV filter (450-490 nm). Three hundred
565 cells per sample were counted in tetraplicates for each dose point. Cells were scored as viable,
566 apoptotic or necrotic as judged by the staining, nuclear morphology and membrane integrity, and
567 percentages of apoptotic and necrotic cells were then calculated. Morphological changes were
568 also observed and photographed. The amount of 200 μ L of dye mixture (100 μ L/mg AO and 100
569 μ L/mg EB in distilled water) was mixed with 2 mL cell suspension (30,000 cells/mL) in 6-well
570 plate. The suspension was immediately examined and viewed under Olympus inverted
571 fluorescence microscope (Ti-Eclipse). We observed untreated cells as controls and cells treated
572 with testing material IC₅₀ concentrations for 24 h of exposure. HepG2 were seeded in a 24-well
573 plate (50,000 cells per well). After 24 h of cells incubation, the medium was replaced with 100
574 μ L medium containing IC₅₀ dose of testing material. Untreated cells served as the control. After
575 24 h, aspirate the media and treat with prepared dye and observe under the fluorescent
576 microscope.

577

578 Hoechst 33342 (H342) staining

579 Stock H342 solution should be originally suspended in dH₂O at a 1mM concentration
580 (H342 will precipitate in PBS). This procedure is very sensitive to cell concentration and pH of
581 the media. Cells should be approximately $1-2 \times 10^6$ /ml, in buffered media, pH 7.2. It is also
582 helpful to include 2% fetal calf serum to maintain the cells. Add H342 dye from the stock
583 solution to cell suspension to respective final concentration. Cells are then incubated at 37^o C for
584 1 hour. Drug was added and incubated for 24 and 48 hours. Time is a critical factor due to the
585 transport of the dye. Typically, 30 minutes is a minimum, but it is important to remember that the
586 signal may begin to degrade after ~120 minutes. It is recommended that the staining kinetics be

587 empirically defined. Analyze apoptosis under fluorescent microscope after incubation. Washing
588 is not recommended.

589

590 **Computational details**

591 Computational studies on the complexes have been performed using HEX 6.3 software
592 which is an interactive molecular graphics program for the interaction, docking calculations, and
593 to identify possible binding site of the biomolecules [51]. The density functional theory (DFT)
594 calculations at B3LYP level were carried out using the GAUSSIAN09 program [52]. The
595 geometries of the complexes under study were optimized using standard 6-31G** basis sets for
596 N, C and H elements and LANL2DZ for Cobalt with effective core pseudo potentials [53]. The
597 coordinates of metal complexes were taken from their optimized structure as a .mol file and were
598 converted to pdb format using GaussView software. The crystal structure of B-DNA (PDB ID:
599 1BNA) is retrieved from the protein data bank [54]. All possible poses have been considered as
600 starting points and the docking analysis was performed. The default parameters were used for the
601 docking calculation with correlation type shape only, FFT mode at 3D level, grid dimension of 6
602 with receptor range 180 and ligand range 180 with twist range 360 and distance range.
603 Visualization of the docked systems has been further analyzed with PyMOL software package
604 [55].

605

606 **Acknowledgments**

607 K. Nagaraj sincerely acknowledges the UGC- COSIST and DST-FIST programmes of
608 the Department of Chemistry, Bharathidasan University for UGC-RFSMS fellowship. Financial
609 assistance from the CSIR (Grant No. 01(2461)/11/EMR-II), DST (Grant No. SR/S1/IC-13/2009)
610 and UGC (Grant No. 41-223/2012(SR) sanctioned to Prof. S. Arunachalam are also gratefully
611 acknowledged. G. V thanks University Grants Commission (UGC), India for the financial
612 support in the form of BSR Meritorious Student Fellowship. P. V thanks Department of Science
613 and Technology (DST), India for Major Research Project (Ref. No: SB/S1/PC-52/2012).

614

615 **References**

616 1 A. D. Miller, *Angew. Chem. Int. Ed. Eng.*, 1998, **37**, 1768-1785.

- 617 2 J. P. Behr, *Tetrahedron Lett.*, 1986, **27**, 5861-5864.
- 618 3 S. M. Melnikov, and V. G. Sergeyev, *J. Am. Chem. Soc.*, 1995, **117**, 9951-9956.
- 619 4 C. H. Spink, and , J. B. Chaires, *J. Am. Chem. Soc.*, 1997, **119**, 10920-10928.
- 620 5 S. M. Melnikov, V. G. Sergeyev, and K. Yoshizava, *J. Am. Chem. Soc.*, 1995, **117**, 2401-
621 2408.
- 622 6 S. Marchetti, G. Onori and C. Cametti, *J. Phys. Chem. B* 2005, **109**, 3676-3680.
- 623 7 D. Matulis, I. Rouzina and V. A. Bloomfield, *J. Am. Chem. Soc.*, 2002, **124**, 7331-7342
- 624 8 R. Dias, S. Melnikov, B. Lindman and M. G. Miguel, *Langmuir* 2000, **16**, 9577-9583.
- 625 9 Y. L. Wang, P. L. Dubin and H. W. Zhang, *Langmuir* 2001, **17**, 1670-1673.
- 626 10 S. Bhattacharya and P. V. Dileep, *Bioconjugate Chem.*, 2004, **15**, 508-519.
- 627 11 A. Bajaj, P. Kondaiah and S. Bhattacharya, *Bioconjugate Chem.*, 2007, **18**, 1537-1546.
- 628 12 J. Zhou, K. T Shum, J. C. Burnett and J. J. Rossi, *Pharmaceuticals* 2013, **6**, 85-107.
629 doi:10.3390/ph6010085.
- 630 13 M. Kwiat, R. Elnathan, M. Kwak, J. W. de Vries, A. Pevzner, Y. Engel, L. Burstein, A.
631 Khatchtourints, A. Lichtenstein, E. Flaxer, A. Herrmann and F. Patolsky, *J. Am. Chem.*
632 *Soc.*, 2012, **134**, 280-92.
- 633 14 A. M. Pyle, J. P. Rehmman, R. Meshoyrer, C. V. Kumar, N. J. Turro and J. K. Barton, *J.*
634 *Am. Chem. Soc.*, 1989, **111**, 3051-3058.
- 635 15 A. M. Badawi, M. A. S. Mohamed, M. Z. Mohamed and M. M. Khowdairy, *J. Cancer*
636 *Res.*, 2007, **3**, 198-206.
- 637 16 S. Bhattacharya and S. S. Mandal, *Biochim. Biophys. Acta* 1997, **1323**, 29-44.
- 638 17 Y. Ni, D. Li and S. Kokot, *Anal. Biochem.*, 2006, **352**, 231-242.
- 639 18 J. R. Thomas and P. J. Hergenrother, *Chem. Rev.*, 2008, **108**, 1171-1224.
- 640 19 J. Gallego and G. Varani, *Acc. Chem. Res.*, 2001, **34**, 836-843.
- 641 20 C. S. Chow and J. K. Barton, *Biochemistry* 1992, **31**, 5423-5429.
- 642 21 H. Xu, H. Deng, Q. L. Zhang, Y. Huang, J. Z. Liu and L. N. Ji, *Inorg. Chem. Commun.*,
643 2003, **6**, 766-768.
- 644 22 M. D. M. Ismal, P. Pandya, S. R. Chowdhury, S. Kumar and G. S. Kumar, *J. Mol. Struct.*,
645 2008, **891**, 498-507.
- 646 23 K. Nagaraj and S. Arunachalam, *New J. Chem.* DOI: 10.1039/c3nj00832k
- 647 24 K. Nagaraj and S. Arunachalam, *Inter. J. Biol. Macro. Mol.*, 2013, **62**, 273-280.

- 648 25 K. Nagaraj and S. Arunachalam, *Aust. J. Chem.*, 2013, **66**, 930-937.
- 649 26 K. Nagaraj and S. Arunachalam, *J. Biomol. Str. Dyn.* (DOI:
650 10.1080/07391102.2013.879837).
- 651 27 K. Nagaraj and S. Arunachalam, *Z. Phys. Chem.*, 2013, **227**, 1-19.
- 652 28 K. Nagaraj and S. Arunachalam, *Trans. Met. Chem.*, 2012, **37**, 423-429.
- 653 29 K. Nagaraj and S. Arunachalam, *Trans. Met. Chem.*, 2013, **38**, 649-657.
- 654 30 K. Nagaraj and S. Arunachalam, *Monatsh. Chem.*, (DOI 10.1007/s00706-013-1080-x).
- 655 31 K. Nagaraj and S. Arunachalam, *J. Inclu. Phenom. Macro. Chem.*, (DOI 10.1007/s10847-
656 013-0365-3).
- 657 32 K. Nagaraj, S. Sakthinathan and S. Arunachalam, *J. Fluorescence* (DOI 10.1007/s10895-
658 013-1332-5).
- 659 33 K. Nagaraj, S. Ambika, S. Rajasri, S. Sakthinathan, S. Arunachalam, *Colloids and*
660 *Surfaces B: Biointerfaces* 2014, **122**, 151-157
- 661 34 D. Gibson, *Dalton Trans.* 2009, 10681-10689.
- 662 35 K. J. Davis, J. A. Carrall, B. Lai, J. R. Aldrich-Wright, S. F. Ralpa, C. T. Dillon,
663 *Dalton Trans.* 2012, **41**, 9417-9426.
- 664 36 A. Casini, J. Reedijk, *Chem. Sci.* 2012, **3**, 3135-3144.
- 665 37 C. Deegan, M. McCann, M. Devereux, B. Coyle, D. A. Egan, *Cancer Lett.* 2007, **247** 224-
666 233.
- 667 38 M. McCann, M. Gerghty, M. Devereux, D. O'Shea, J. Mason, L. O'Sullivan, *Met. Based*
668 *Drugs* 2000, **7**, 185-193.
- 669 39 a) Y. Xiong, L. N. Ji, *Coord. Chem. Rev.*, 1999, **711**, 185-186; b) P. Hohenberg and W.
670 Kohn, *Phys. Rev. B*, 1964, **136**, 864-869; c) A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 1372-
671 1377.
- 672 40 M. F. Reichmann, S. A. Rice, C. A. Thomas and P. Doty, *J. Am. Chem. Soc.*, 1954, **76**,
673 3047-3053.
- 674 41 Bonniticha *et al.*, *Dalton Trans.* 2012, **41**, 11293-11304.
- 675 42 L. N. Ji, X. H. Zou and J. G. Liu, *Coord. Chem. Rev.*, 2001, **513**, 216-217.

- 676 43 S. Ghosh, A. C. Barve, A. A. Kumbhar, A. S. Kumbhar, V. G. Puranik, P. A. Datar, U. B.
677 Sonawane and R. R. Joshi, *J. Inorg. Biochem.*, 2006, **100**, 331-343.
- 678 44 A. A. Vlcek, *Inorg. Chem.*, 1967, **6**, 1425-1427.
- 679 45 J. G. Collins, A. D. Sleeman, J. R. Aldrich-Wright, I. Greguric and T. W. Hambley, *Inorg*
680 *Chem.*, 1998, **37**, 3133-3141.
- 681 46 J. Z. Wu, B. H. Ye, L. Wang, L. N. Ji, J. Y. Zhou, R. H. Li and Z. Y. Zhou, *J. Chem. Soc.*
682 *Dalton Trans.*, 1997, 1395-1401.
- 683 47 R. E. Kitson, *Anal. Chem.*, 1950, **22**, 664-667.
- 684 48 J. K. Barton, J. M. Goldberg, C. V. Kumar and N. J. Turro, *J. Am. Chem. Soc.*, 1986, **108**,
685 2081-2088.
- 686 49 M. L. Morris and D. H. Busch, *J. Am. Chem. Soc.*, 1960, **82**, 1521-1524.
- 687 50 D. L. Spector, R. D. Goldman and L. A. Leinwand, *Culture and biochemical Analysis of*
688 *cells, In: Cell: A Laboratory Manual*, vol. 1, Cold Spring Harbor Laboratory Press, Cold
689 Spring Harbor, New York, 1998.
- 690 51 J. B. Foresman, A. E. Frisch, *Exploring Chemistry with Electronic Structure Methods*,
691 second ed., Gaussian, Inc., Pittsburgh, PA, 1996.
- 692 52 K. Fukui, T. Yonezawa and H. Shingu, *J. Chem. Phys.*, 1952, **20**, 722-725
- 693 53 I. Fleming, *Frontier Orbital and Organic Chemical Reaction*, Wiley, New York, 1976.
- 694 54 D. Reha, M. Kabelac, F. Ryjacek, J. Sponer, J.E. Sponer, M. Elstner, S. Suhai and P.
695 Hobza, *J. Am. Chem. Soc.*, 2002, **124**, 3366-3376.
- 696 55 N. Kurita and K. Kobayashi, *Comput. Chem.*, 2000, **24**, 351-357.
- 697 56 L. Jin and P. Yang, *Polyhedron* 1997, **16**, 3395-3398.
- 698 57 T. I. A. Gerber, *J. Coord. Chem.*, 2003, **56**, 1397-1407.
- 699 58 M. R. Rosenthal, *J. Chem. Educ.*, 1973, **50**, 331-335.
- 700 59 J. D. Miller and R. H. Prince, *J. Chem. Soc., A* 1969, 519-520.
- 701 60 S. Castellano, H. Gunther and S. Ebersole, *J. Phys. Chem.*, 1965, **69**, 4166-4176.
- 702 61 P. C. Griffiths, I. A. Fallis, T. Chuenpratoom and R. Watanesk, *Adv Colloid Int Sci.*, 2006,
703 **122**, 107-117.
- 704 62 P. Mukerjee, *J. Phys. Chem.*, 1962, **66**, 1375-1376.
- 705 63 J. J. Galan, A. Gonzalez-Perez and J. R. Rodriguez, *J. Therm. Anal. Calorim.*, 2003, **72**,
706 465-470.

- 707 64 A. Gonzalez-Perez, J. C. Del Castillo, T. Czapkiewicz and J. R. Rodrigue, *Colloid Polym.*
708 *Sci.*, 2002, **280**, 503-508.
- 709 65 R. Zana, *J. Colloid Interface Sci.*, 1980, **78**, 330-337.
- 710 66 R. F. Pasternack, E. J. Gibbs and J. J. Villafranca, *Biochemistry* 1983, **22**, 2406-2414.
- 711 67 A. M. Pyle, J. P. Rehmman, R. Meshoyrer, C. V. Kumar, N. J. Turro and J. K. Barton, *J.*
712 *Am. Chem. Soc.*, 1989, **111**, 3051-3058.
- 713 68 M. T. Carter, M. Rodriguez and A. J. Bard, *J. Am. Chem. Soc.*, 1989, **111**, 8901-8911.
- 714 69 P. Tamil Selvi, and M. Palaniandavar, *Inorg. Chim. Acta*, 2002, **337**, 420-428.
- 715 70 S. Satyanarayana, J. C. Dabroniak and J. B. Chaires, *Biochemistry* 1992, **31**, 9319-9324
- 716 71 K. R. Sangeetha Gowda, H. S. Bhoiyya Naik, B. Vinay Kumar, C. N. Sudhamani, H. V.
717 Sudeep, T. R. Ravikumar Naik, G. Krishnamurthy, *Spectrochim. Acta A: Mol. Biomol.*
718 *Spec.* 2013, **105**, 229-37.
- 719 72 S. Nehru, S. Arunachalam, R. Arun, K. Premkumar, *J. Biomol. Str. Dyn.* 2014, **32**, 1876-
720 1888.
- 721 73 K. Fukui, T. Yonezawa and H. Shingu, *J. Chem. Phys.*, 1952, **20**, 722-725
- 722 74 I. Fleming, *Frontier Orbital and Organic Chemical Reaction*, Wiley, New York, 1976.
- 723 75 N. Kurita and K. Kobayashi, *Comput. Chem.*, 2000, **24**, 351-357
- 724 76 A. L. Tenderholt, *QMForge: A Program to Analyze Quantum Chemistry Calculations*,
725 Version 2.3.2, <http://qmforge.sourceforge.net>.
- 726 77 J. D. McGhee, *Biopolymers* 1976, **15**, 1345-1375
- 727 78 M. Gellert, C. Smith, D. Neville and G. Felsenfeld, *J. Mol. Biol.*, 1965, **11**, 445-457.
- 728 79 I. Haq, P. Lincoln, D. Suh, B. Norden, B. Z. Chowdhry, J. B. Chaires, *J. Am. Chem. Soc.*,
729 1995, **117**, 4788-4796.
- 730 80 V. A. Izumrudov, M. V. Zhiryakova, A. A. Goulko, *Langmuir* 2002, **18**, 10348-10356.
- 731 81 V. A. Izumrudov, M. V. Zhiryakova and S. E. Kudaibergenov, *Biopolymers* 2000, **52**, 94-
732 108.
- 733 82 B. C. Baguley and M. LeBret, *Biochemistry* 1984, **23**, 937-943.
- 734 83 T. B. Wyman, F. Nicol, O. Zelphati, P. V. Scaria, C. Plank and F. C. Szoka, *Biochemistry*
735 1997, **36**, 3008-3017.
- 736 84 J. R. Lakowicz and G. Webber, *Biochemistry* 1973, **12**, 4161-4170.

- 737 85 P. Uma Maheswari, and M. Palaniandavar, *J. Inorg. Biochem.*, 2004, **98**, 219-230.
- 738 86 M. T. Carter and A. J. Bard, *J. Am. Chem. Soc.*, 1987, **109**, 7528-7530.
- 739 87 L. M. Chen, J. Liu, J. C. Chen, C. P. Tan, S. Shi, K. C. Zheng and L. N. Ji, *J. Inorg.*
740 *Biochem.*, 2008, **102**, 330-341.
- 741 88 S. Satyanaryana, J. C. Daborusak and J. B. Chaires, *Biochemistry* 1993, **32**, 2573-2584; b)
742 J. M. Brown, *Cancer Res* 1999, **59**, 5863-5870; c) B. G. Wouters, S. A. Wepler, M.
743 Koritzinsky, W. Landuyt, S. Nuyts, J. Theys, R. K. Chiu, P. Lambin, *Eur. J Cancer* 2002,
744 **38**, 240-257.
- 745 89 B. Coyle, P. Kinsella, M. McCann, M. Devereux, R. O. Connor, M. Clynes, K. Kavanagh,
746 *Induction of apoptosis in yeast and mammalian cells by exposure to 1,10-phenanthroline*
747 *metal complexes*, *Toxicology in Vitro : an International Journal Published in Association*
748 *With BIBRA 18* (2004) 63-70.
- 749 90 B. Coyle, M. McCann, K. Kavanagh, M. Devereux and M. Geraghty, *Biometals* 2003, **16**,
750 321-329.
- 751 91 S. Osinsky, I. Levitin, L. Bubnovskaya, A. Sigan, I. Ganusevich, *Exper. Oncol.* 2004, **26**,
752 140-144.
- 753 92 A. M. Badawi, M. MekawiAS, M. Z. Mohamed, M. M. Khowdairy, *J. Cancer Res.*
754 *Therapeu.* 2007, **3**, 198-206.
- 755 93 D. Baskic, S. Popovic, P. Ristic, N. N. Arsenijevic, *Cell Biology International* 2006, **30**,
756 924-932.

Scheme captions

759 Scheme 1. Synthetic procedure of surfactant cobalt(III) complexes

Figure captions

761 Figure. 1. Electrical conductivity vs. complex **(1)** concentration in aqueous solutions.

762 Figure. 2. Absorption spectra of complex **(1)** (Above cmc): in the absence (dotted line) and in the
763 presence (solid lines) of increasing amounts of CT DNA. {Inset: Plot of $[DNA] / (\epsilon_a - \epsilon_f)$ vs.
764 $[DNA]$ }. $[complex] = 1.0 \times 10^{-4}$ M; $[DNA] = 0-9.1 \times 10^{-5}$ M.

765 Figure. 3. Absorption spectra of complex **(1)** (Below cmc): in the absence (dotted line) and in the
766 presence (solid lines) of increasing amounts of CT DNA. {Inset: Plot of $[DNA] / (\epsilon_a - \epsilon_f)$ vs.
767 $[DNA]$ }. $[complex] = 1.0 \times 10^{-6}$ M; $[DNA] = 0-9.1 \times 10^{-5}$ M.

768 Figure. 4. Docked pose of surfactant Co(III) Complexes bound to the CT DNA: (a) Complex **(1)**
769 with B-DNA (b) Complex **(2)** with B-DNA.

770

771 Figure. 5. Emission spectra of EB bound to CT DNA: in the absence and in the presence of
772 surfactant Co(III) complex **(1)**. $[EB] = 2 \times 10^{-5}$ M, $[DNA] = 1 \times 10^{-4}$ M, $[Complex] = 0-1.43 \times 10^{-6}$

773 Figure. 6. Photomicrographs of control and AO and EB stained HepG2 liver cancer cells
774 incubated for 24 hours with surfactant Co(III) complexes **(1)** and **(2)**. A,B Untreated control
775 cells. C,D surfactant Co(III) complex treated control cells. ; Viable (light green), early apoptotic
776 (bright green fluorescing), late apoptosis (red to orange fluorescing) and necrosis (red
777 fluorescing) cells were observed. Magnification at 20x.

778 Figure. 7 Surfactant Co(III) complexes **(1)** and **(2)** induces apoptosis in HepG2 liver cancer cells.
779 Representative fluorescent micrographs of HepG2 liver cancer cells stained with Hoechst 33342
780 fluorescent dye after the compound exposure for 24 and 48 hours. I, II Untreated control cells;
781 A,B,C and, D surfactant Co(III) complex treated control cells. A, C – 24 hours; B, D - 48 hours.
782 Magnifications at 20X.

783

784

785

Table captions

786 Table 1. CMC values of the surfactant Co(III) complex **(1)** in aqueous solution.

787 Table 2. The binding constant (K_b) and Stern-Volmer constant (K_{SV}) of surfactant Co(III)
788 complexes **(1)** and **(2)** with CT DNA.

789 Table 3. Frontier molecular orbital compositions (%) of surfactant Co(III) complexes **(1)** and **(2)**
790 at the B3LYP/LANL2DZ level.

791 Table 4. Cyclic voltammetric data (mV) of surfactant Co(III) complexes **(1)** and **(2)**, a scan rate
792 of 100 mV/s with phosphate buffer as supporting electrolyte.

793 Table 5. IC₅₀ by MTT-3-(4-5 dimethylthiazol-2-yl) 2-5 diphenyl-tetrazolium bromide method.


794

795

Schemes

796

797



Scheme 1. Synthetic route of surfactant complexes (1) and (2)


798

799

800

801

Figures



802

803

Fig. 1

804

805

806

807

808

809

810

811

812

813

814

815

816

817





Fig. 3



818


819

Fig. 4

820

821

822



823

824


825

826

827

Fig. 5

828




829

830

Fig. 6

831



832

833

Fig. 7

834

835

126

836

837

838

839

840

841

Tables

842

Table 1

843

Temp.	CMC $\times 10^5$	$-\Delta G_{mic}^0$ (kJ mol $^{-1}$)	$-\Delta H_{mic}^0$ (kJ mol $^{-1}$)	$T\Delta S_{mic}^0$ (kJ mol $^{-1}$)
303K	9.45	35.0 \pm 0.2	11.3 \pm 0.3	23.8 \pm 0.4
308K	9.64	57.3 \pm 0.1	18.8 \pm 0.1	38.5 \pm 0.1
313K	9.97	78.5 \pm 0.1	26.3 \pm 0.2	52.2 \pm 0.1
318K	10.5	99.9 \pm 0.4	34.3 \pm 0.1	65.6 \pm 0.2
323K	10.89	114.9 \pm 0.4	40.3 \pm 0.1	74.7 \pm 0.2

850

851

852

Table 2

Surfactant Co(III) Complexes	K_b (M $^{-1}$)		Hypochromism	K_{sv} (M $^{-1}$)	
	Below CMC	Above cmc			
Complex (1)	(5.7 \pm 0.2) $\times 10^5$	(1.3 \pm 0.3) $\times 10^6$	29	31	0.1573
Complex (2)	(2.4 \pm 0.1) $\times 10^6$	(3.1 \pm 0.2) $\times 10^6$	34	37	0.1829

853

854

855

Table 3

Energy Levels	Complex (1)			Complex (2)		
	Co	L1	L2	Co	L1	L2
HOMO-3	0.00	0.00	100.00	0.00	0.00	100.00
HOMO-2	0.43	95.84	3.73	0.00	0.00	100.00
HOMO-1	0.09	40.64	59.27	4.36	3.65	91.99
HOMO	0.05	6.86	93.09	0.91	0.27	98.82
LUMO	0.07	85.15	14.78	53.55	43.02	3.43
LUMO+1	53.15	45.70	1.15	52.04	17.35	30.62
LUMO+2	51.58	17.57	30.85	0.66	96.65	2.69
LUMO+3	0.82	96.35	2.83	1.43	97.58	1.00

856

857

Table 4

858

859

860

861

862

863

864

865

866

867

Surfactant Co(III) Complexes	E_{pc1} (mV)	E_{pa1} (mV)	ΔE_p (mV)	$E_{1/2}$ (mV)	i_{pa}/i_{pc}	E_{pc2} (mV)
Complex (1)	-718.5	+13.5	+732.0	-352.5	0.6	-1208.5
Complex (1) + DNA	-714.5	+7.5	+721.9	-353.5	0.7	-1202.5
Complex (2)	-238.5	+56.5	+295.0	-91.0	1.5	-908.5
Complex (2) + DNA	-258.5	+167.5	+426.0	-45.5	1.8	-838.5

868

Table 5

Complexes	IC_{50} (μ m)	
	24 h	48 h
(1)	(6.8 \pm 0.2)	(6.1 \pm 0.2)
(2)	(6.0 \pm 0.2)	(5.0 \pm 0.2)

868

Graphical Abstract

